At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Ranolazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation
In Brief
A Phase 4 clinical trial evaluating Ranolazine for Hypertrophic Cardiomyopathy. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical therapy. This is a small, pilot, open-label (non-randomized) study of an approved drug for the treatment of angina in a novel patient population (adult patient population with hypertrophic cardiomyopathy).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertrophic Cardiomyopathy
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionNov 2015
Study CompletionMay 2016
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartNov 1, 2012
Primary CompletionNov 1, 2015
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.7 years ago
Interventions
Ranolazinedrug